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REVIEW
Abstract: Prescribing for older people is challenging because of the paucity of clinical trial
evidence of therapeutic benefit in this population and the presence of evidence that older
people are at increased risk of adverse drug reactions. The outcomes of pharmacotherapies in
older people depend on age-related changes in both pharmacokinetics and pharmacodynamics.
Of the pharmacokinetic changes, those in hepatic metabolism are the most significant. Recent
advances in biogerontology have improved our understanding of changes that occur in hepatic
pharmacokinetics in older people. Knowledge of age-related changes in hepatic metabolism
can guide prescribing and help reduce the risk–benefit ratio of using medications in older
people.
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Medication use by older people
Older people are major users of medications because of the increased prevalence of
chronic diseases and increased susceptibility to acute illness with age. On average,
older people use two to five regular prescription medications, and 15%–40% use five
or more medications (polypharmacy) (Table 1) (Helling et al 1987; Stewart and Cooper
1994; Anderson and Kerluke 1996; Barat et al 2000; Chen et al 2001; Jorgensen et al
2001; Linjakumpu et al 2002; Byles et al 2003). Use of medications by older people
has continued to increase over the past two decades (Stewart et al 1991; Linjakumpu
et al 2002) and because of the increased risk of disease, older people should benefit
from medications (Ebrahim 2002). However, the evidence base for prescribing to
older people is limited with regard to both efficacy and safety (Bugeja et al 1997).
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Clinical implications of changes in hepatic drug
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Table 1 Prevalence of polypharmacy in community-dwelling older people
Mean or
median Definition
Age number of Polypharmacy of
group medications (%) polypharmacy Place Reference
> 64  3.1 (1990–1991) 19 (1990–1991) 5 or more Finland Linjakumpu et al
3.8 (1998–1999) 25 (1998–1999) 2002
65–74 2.03 11 5 or more UK Chen et al 2001
> 75 2.47 15
> 64 4 53 4 or more Australia Byles et al 2003
including OTC
65–74 2.2  24 6 or more Canada Anderson et al
1996
> 75 3.8 37
> 75 4.2 34 5 or more Denmark Barat et al 2000
> 65 4.8 (female) 39 5 or more Sweden Jorgensen et al
3.8 (male) 2001
Abbreviations: OTC, over the counter.Therapeutics and Clinical Risk Management 2005:1(2) 152
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Increasing age is correlated with increasing incidence of
adverse drug reactions both in hospital and in the community
(Hurwitz and Wade 1969; Kellaway and McCrae 1973;
Carbonin et al 1991; Atkin and Shenfield 1995; Martin et al
1998; Gholami and Shalviri 1999; Pouyanne et al 2000;
Bordet et al 2001). Susceptibility of older people to adverse
drug reactions is considered to be secondary both to extrinsic
factors (prescribing and medication management) and
intrinsic factors (pharmacokinetics and pharmacodynamics)
(Nolan and O’Malley 1988). This review will describe the
pharmacokinetic changes that occur as a result of aging
changes in the liver. It will highlight clinical implications
of these changes and guide prescribing to maximize
therapeutic effects and reduce the subset of adverse reactions
due to altered pharmacokinetics in older people.
Pharmacokinetic considerations
related to the aging liver
Hepatic clearance (Clliver) is illustrated by the formula:
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where, Ca = concentration of drug in portal vein and hepatic
artery, Cv = concentration of drug in hepatic vein, Q = sum
of hepatic portal and arterial blood flow, and E = steady state
extraction ratio. The clearance of medications by the liver
depends on hepatic blood flow and intrinsic clearance
(enzyme activity and mass). The clearance of highly
extracted substrates is predominantly determined by hepatic
blood flow (flow limited), while that of poorly extracted
substrates is influenced by intrinsic clearance (capacity
limited) and in some cases, protein binding. Aging is
associated with a reduction of approximately 40% in hepatic
blood flow and 30% in liver mass (McLean and Le Couteur
2004). Impaired hepatic drug clearance in older people has
been attributed to these changes (Woodhouse and Wynne
1988).
The clearance of flow-limited drugs is reduced to a
greater extent than that of capacity-limited drugs in older
people (Table 2). The metabolism of flow-limited drugs is
reduced by approximately 40%, consistent with the
reduction in blood flow in older people. The in vitro
metabolism of many capacity-limited drugs is relatively
preserved, consistent with preservation of the content,
activity, and gene expression of phase I and II drug
metabolizing enzymes with age (Le Couteur and McLean
1998; Kinirons and O’Mahony 2004) (Table 2).
Even so, there seems to be an age-associated selective
impairment of phase I drug metabolism with no significant
reduction in phase II metabolism (Le Couteur and McLean
1998) (Table 2). Even though there is no change in in vitro
activity of phase I enzymes with age (no reduction in enzyme
expression [Schmucker et al 1990] or activity [Hunt et al
1992]), most drugs metabolized by phase I pathways have
reduced clearance in older people (Le Couteur and McLean
1998). The paradox of reduced phase I drug metabolism in
older people (Schmucker 2001) has been explained by the
oxygen delivery hypothesis (Le Couteur and McLean 1998).
Phase I enzymes are more oxygen dependent than phase II
enzymes. The normal endothelium of the hepatic sinusoid
is attenuated and fenestrated and does not impair oxygen
transfer. However, in aged rats (Le Couteur et al 2001),
baboons (Cogger et al 2003), and humans (McLean et al
2003) the sinusoidal endothelium is thickened and
defenestrated and there is associated deposition of collagen
and basal lamina formation. These structural changes could
Table 2 The influence of old age in humans on the metabolism
of drugs and other compounds that undergo phase I, phase II,
capacity-limited, and flow-limited metabolism
Hepatic metabolism Reduced Unchanged
Flow-limited pethidine
morphine
propranolol
verapamil
amitryptiline
lignocaine
Capacity-limited theophylline diazepam
phenytoin
salicylic acid
valproic acid
warfarin
Phase I ibuprofen warfarin
lignocaine caffeine
diltiazem phenytoin
propranolol
theophylline
impramine
amitryptiline
verapamil
Phase II morphine isoniazid
oxazepam
paracetamol
salicylic acid
temazepam
Source: Adapted from Le Couteur DG, McLean AJ. 1998. The aging liver: drug
clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet, 34:
359–73. Reproduced with permission from Adis International.Therapeutics and Clinical Risk Management 2005:1(2) 153
Hepatic drug metabolism in older people
reduce oxygen or even drug transfer to the hepatocytes (Le
Couteur et al 2005). We recently demonstrated the
importance of the hepatic sinusoidal endothelium as a barrier
to drug transfer in a study of the hepatic disposition of
liposomal doxorubicin. The liposomes were restricted to
the sinusoidal lumen, presumably secondary to steric
exclusion by fenestrations in the sinusoidal endothelium,
explaining the longer half-life and reduced hepatic extraction
of liposomal doxorubicin compared with doxorubicin
(Hilmer et al 2004).
Phase II metabolism generally is not affected by normal
aging. However, it may be impaired in frail older people.
This is seen with paracetamol conjugation, which is
preserved in healthy older people (Miners et al 1988) but
impaired in frail, hospitalized older people (Wynne et al
1990).
The reduction in hepatic metabolism with age is also
important in first-pass metabolism and therefore oral
bioavailability of medications. In older people, drugs
undergoing extensive first-pass metabolism, such as
propranolol and verapamil (Wilkinson 1997) have increased
bioavailability. However, prodrugs, such as perindopril
(Todd and Fitton 1991) may have slower first-pass activation
in the aged liver.
The phase III hepatic pathway is the transport of drugs
into the bile, predominantly by P-glycoprotein and other
transporters in bile canaliculi (Yamazaki et al 1996;
Marzolini et al 2004). Transporters including P-glycoprotein
are also involved in efflux of compounds (including drugs)
from the intestines (Chan et al 2004). There are no human
studies on phase III hepatic metabolism in aging. Expression
and activity of P-glycoprotein in lymphocytes are increased
with age in rodents in some studies (Gupta 1995). Other
studies in young and old people have demonstrated a
decrease in the activity of P-glycoprotein in T lymphocytes
(Machado et al 2003) with age, with no change in its function
in natural killer cells (Machado et al 2003; Brenner and
Klotz 2004). In each subject, the expression of
P-glycoprotein in different organs is not clearly associated
(von Richter et al 2004). There is wide (40x) genetically
determined inter-individual variation in expression of
P-glycoprotein (Kim et al 1999) and this variability would
be expected to be even greater as heterogeneity increases
with age. Surprisingly, the function of P-glycoprotein in
natural killer cells differs between the CC and TT genotypes
in young but not elderly subjects (Brenner and Klotz 2004).
This is probably because the increasing heterogeneity with
age is not due to genetic factors. Recently, P-glycoprotein
expression and function has been described in young,
intermediate, and old rats in a range of tissues important for
drug disposition. P-glycoprotein expression increased with
age in lymphocytes and the liver, decreased in the kidneys,
and did not change significantly and was very variable in
intestinal microsomes and blood brain barriers (Warrington
et al 2004). If there is a similar trend in aging humans, then
changes in P-glycoprotein may increase the biliary excretion
and decrease renal excretion of drugs with variable effects
on intestinal absorption.
Implications of hepatic
pharmacokinetic changes when
prescribing for older people
Hepatic changes must be considered in the context of other
pharmacokinetic changes and pharmacodynamic changes
in older people. However, of the pharmacokinetic changes
with age, changes in hepatic metabolism are the most
significant (McLean and Le Couteur 2004). Age-related
changes in drug absorption (Mangoni and Jackson 2004),
distribution (higher fat: muscle ratio) (Turnheim 1998), and
protein binding (Benet and Hoener 2002) are not usually
clinically significant. Renal elimination of drugs is reduced
with age to a lesser extent than was previously believed
(McLean and Le Couteur 2004) but remains important for
renally excreted drugs with narrow therapeutic-toxic
windows. This is especially true with the onset of acute renal
failure, eg, contrast nephropathy. Consequently, impaired
hepatic metabolism, which affects both bioavailability and
hepatic clearance, is a major pharmacokinetic factor to
consider when prescribing for older people.
Dose adjustment for older people
Aging changes in hepatic pharmacokinetics suggest that
initial doses of most drugs with high hepatic extraction ratios
and particularly those that undergo phase I metabolism
should be reduced by approximately 40% in older people
to achieve similar pharmacokinetic profiles to young people
(Table 2). The adjustment in maintenance dose, D´ m, required
to correct for a decline in metabolic clearance can be
calculated from the formula:
mm
fCL
DD
f CL
′
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′
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Where, Dm is the maintenance dose in a young adult, ƒ is
the drug bioavailability, and CL the clearance (TurnheimTherapeutics and Clinical Risk Management 2005:1(2) 154
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2003). In contrast, intravenous loading doses do not require
adjustment for age, and should be adjusted only to the
patient’s volume of distribution, which can be estimated
using their weight.
It is important to consider whether the drug is a prodrug
and whether it has active or toxic metabolites in selecting a
starting dose. For example, HMG-CoA reductase inhibitors
(Table 3) have high hepatic extraction ratios and are
processed by phase I, II, and III pathways in the liver (Igel
et al 2002). Their therapeutic effects are related to their
actions in the liver, but toxic effects are related to drug
concentrations in both the liver and the periphery.
Simvastatin is a prodrug and conversion to its active
metabolites by phase I metabolism will be less efficient in
older people. The dose may need to be maintained in older
people for therapeutic effect but patients may be at increased
risk of toxic effects from the accumulated prodrug.
Pravastatin and atorvastatin are not prodrugs. Pravastatin is
metabolized to inactive metabolites while atorvastatin has
active metabolites, which undergo biliary excretion. In older
people, lowering the dose of pravastatin and atorvastatin by
about 40% should correct for the decreased phase I
metabolism to give a similar pharmacokinetic profile to a
standard dose in a younger person. This is supported by
clinical trial evidence. A 20-mg dose of pravastatin gives a
larger AUC for pravastatin in older than younger people,
but the pharmacokinetics of the metabolite SQ 31 906 are
similar in both age groups (Pan et al 1993). A 20-mg dose
of atorvastatin has a Cmax 42.5% higher, AUC 27.3% greater,
and elimination half-life 36.2% longer in older than younger
people. Phase III metabolism of HMG-CoA reductase
inhibitors depends on P-glycoprotein, and if the expression
and activity of this protein is increased in the livers of older
people as it is in the livers of older rats (Warrington et al
2004), then biliary excretion of the metabolites may be more
efficient in older people.
Adverse drug reactions
There is a strong association between the risk of adverse
drug reactions and old age (Beyth and Shorr 1999). Some
evidence suggests that rather than being an independent risk
factor, age may simply be a marker for comorbidities, altered
pharmacokinetics, and polypharmacy (Figure 1)
(Williamson and Chopin 1980; Leach and Roy 1986;
Carbonin et al 1991; Gurwitz and Avorn 1991; Atkin and
Shenfield 1995; Cooper 1999; Mannesse et al 2000).
Polypharmacy increases the risk of adverse events
(Figure 1), secondary to both cumulation of adverse
reactions to each drug and drug–drug interactions (Rosholm
et al 1998; du Souich 2001). Many predictable drug–drug
interactions occur through induction or inhibition of the
cytochrome P450 pathways of hepatic metabolism (Tanaka
1998). More recently drug–drug interactions have been
recognized in phase III metabolism. One study found
digoxin levels correlated with the number of inhibitors of
P-glycoprotein patients were taking, eg, amiodarone,
atorvastatin, quinine, spironolactone, verapamil (Englund
et al 2004). However, this is more likely to be related to P-
glycoprotein inhibition in the intestines than in the liver.
One of the strongest independent risk factors for
polypharmacy is the prescriber, so attempts to reduce
polypharmacy focus on educating the prescribing doctors.
Inappropriate prescribing can be reduced using “academic
detailing” (Soumerai and Avorn 1990). This includes
assessment of baseline knowledge and motivations for
current prescribing, focusing programs on specific
categories of physicians and on their opinion leaders,
defining clear educational and behavioral objectives,
establishing credibility through a respected organizational
identity, referencing authoritative and unbiased sources of
information, presenting both sides of controversial issues,
stimulating active physician participation in educational
Table 3 Pharmacokinetic data for HMG-CoA reductase
inhibitors
HMG-CoA
reductase
inhibitor Simvastatin Pravastatin Atorvastatin
Prodrug Yes No No
Hepatic extraction 78–87 66 > 70
(% absorbed dose)
Active metabolites Yes No Yes
Source: Adapted from Igel M, Sudhop T, von Bergmann K. 2002. Pharmacology of
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including
rosuvastatin and pitavastatin. J Clin Pharmacol, 42:835–45. Reproduced with
permission from Sage Publications.
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Figure 1 The relationship between polypharmacy and adverse drug reactions.
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interactions, using concise graphic educational materials,
highlighting and repeating the essential messages, and
providing positive reinforcement of improved practices in
follow-up visits. However, we found attempts to reduce
polypharmacy with “academic detailing” and a patient-held
medication card were less effective than introduction of a
government co-payment for prescriptions (Atkin et al 1996).
The introduction of co-payments may decrease the use of
both necessary and unnecessary medications.
Stopping medications can be associated with adverse
drug effects related to withdrawal (Woodward 2000),
recurrence of the underlying condition (Nelson et al 2002),
or alterations in the pharmacokinetics and pharmaco-
dynamics of the patient’s other medications.
Over 80% of adverse drug reactions that require
admission or occur in hospital are the type A, dose-related
kind (Shenfield 2001; Routledge et al 2004). Consideration
of aging pharmacology should be able to reduce those
adverse drug reactions due to high drug concentration at
the site(s) of action.
Many adverse reactions in older people are due to
pharmacodynamic changes (with normal aging and disease)
and loss of compensatory homeostatic mechanisms with
aging. Such adverse drug reactions occur with drug
concentrations in the therapeutic range at the target
receptors. For example, therapeutic serum levels of digoxin
result in adverse drug reactions in older people.
Even type B, idiosyncratic adverse drug reactions, such
as interstitial nephritis and hepatitis with H2-receptor
antagonists appear to be commoner in older people (Fisher
and Le Couteur 2001), and these are not preventable with
our current understanding of aging pharmacology.
Broad implications of age-
associated changes in hepatic
pharmacokinetics
Age-associated changes in the liver affect the metabolism
not only of drugs, but also of other substrates. The
associations between age and neurodegenerative disease,
and age and atherosclerosis may be related to altered hepatic
metabolism of neurotoxins and lipids (Le Couteur et al
2002), respectively.
Conclusions
Unfortunately, there is little clinical trial evidence to guide
prescribing in older people (McLean and Le Couteur 2004).
In addition, older people are a very heterogeneous group.
Therefore, clinical decisions must be made for each
individual with vigilant monitoring for efficacy and adverse
drug reactions. An understanding of impaired hepatic
metabolism of drugs in older people can guide the clinician
in selecting starting doses of medications. Medications that
are prodrugs requiring activation through hepatic
metabolism may be less effective in older people, and
medications that are metabolized for biliary or renal
excretion may require lower or less frequent doses in
older people.
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